Alveus Therapeutics: Valuation, Funding & Investors
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases. The company focuses on programs designed for sustained efficacy, improved tolerability, and reduced treatment burden, including a bifunctional GIPR antagonist/GLP-1R agonist and an amylin-based portfolio spanning injectable and oral modalities.
Leadership & Board
- Current Number of Employees
- 35
- Current LinkedIn Followers
- 3,529
Latest Estimated Valuation
- Total Amount Raised
- $160M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $160M
- Latest Funding Round
- Series A
Company Momentum
PositiveAlveus Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Alveus Therapeutics had 35 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Alveus Therapeutics had 3,529 followers as of November 16, 2026. The number of followers increased by 36 (1.03%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 08, 2026 | Series A | $159.80M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Omega Funds | Series A |
| Avego Bioscience Capital | Series A |
| Andera Partners | Series A |
| Kurma Partners | Series A |
| New Rhein Healthcare Investors | Series A |
| Sanofi Capital | Series A |
Similar Companies
A snapshot of private companies similar to Alveus Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis






